Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma

  • Brentuximab vedotin (SGN-35) is an antibody–drug conjugate with a high selectivity against CD30+ cell lines and more than 300-fold less activity against antigen-negative cells. In the last years, the results of many in vitro and in vivo studies have led to the fast approval of this drug to treat lymphoma patients. Another innovative method to treat tumor cells including lymphoma cells is the use cytokine-induced killer (CIK) cells, which have also been approved and proven to be a safe treatment with only minor adverse events. In this study, a possible additive effect when combining SGN-35 with CIK cells was investigated. The combinational treatment showed that it reduces the viability of CD30+ cell lines significantly in vitro. Additionally, the amount of lymphoma cells was significantly reduced when exposed to CIK cells as well as when exposed to SGN-35. A significant negative effect of SGN-35 on the function of CIK cells could be excluded. These results lead to the assumption that SGN-35 and CIK cells in combination might achieve better results in an in vitro setting compared to the single use of SGN-35 and CIK cells. Further investigations in in vivo models must be conducted to obtain a better understanding of the exact mechanisms of both treatments when applied in combination.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Availability
Metadaten
Document Type:Article
Language:English
Author:Laura Esser, Hans Weiher, Ingo Schmidt-Wolf
Parent Title (English):Int J Mol Sci. (International Journal of Molecular Sciences)
Volume:17
Issue:7
First Page:1056
ISSN:1422-0067
URN:urn:nbn:de:hbz:1044-opus-25300
DOI:https://doi.org/10.3390/ijms17071056
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=27376285
Publisher:MDPI
Place of publication:Basel
Publishing Institution:Hochschule Bonn-Rhein-Sieg
Date of first publication:2016/07/01
Note:
© 2016 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Tag:CD30+ cells; SGN-35; antibody–drug conjugate; cytokine-induced killer (CIK) cells; lymphoma
Departments, institutes and facilities:Fachbereich Angewandte Naturwissenschaften
Institut für funktionale Gen-Analytik (IfGA)
Dewey Decimal Classification (DDC):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Entry in this database:2016/07/06
Licence (German):License LogoCreative Commons - CC BY - Namensnennung 4.0 International